Daratumumab biosimilar (Celltrion)

达雷妥尤单抗生物类似药 (Celltrion)

Report date: 2025/05/15 20:00:08

Base Information

Drug NameDaratumumab biosimilar (Celltrion)
Drug Alias NameCT-P44
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-CD38Antibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrion Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A